View Item 

Show simple item record

Opioid Modulation of Oxytocin Release

dc.contributor.authorMorris, Mark S.en_US
dc.contributor.authorDomino, Edward F.en_US
dc.contributor.authorDomino, Steven E.en_US
dc.date.accessioned2013-04-08T20:49:38Z
dc.date.available2013-04-08T20:49:38Z
dc.date.issued2010-10en_US
dc.identifier.citationMorris, Mark S.; Domino, Edward F.; Domino, Steven E. (2010). "Opioid Modulation of Oxytocin Release." The Journal of Clinical Pharmacology 50(10). <http://hdl.handle.net/2027.42/97182>en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97182
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherParturitionen_US
dc.subject.otherVasopressinen_US
dc.subject.otherMu‐Kappa‐Delta Opioid Receptorsen_US
dc.subject.otherMorphineen_US
dc.subject.otherEndogenous Opioidsen_US
dc.subject.otherMeperidineen_US
dc.subject.otherOxytocinen_US
dc.titleOpioid Modulation of Oxytocin Releaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumObstetrics and Gynecology, University of Michigan, Ann Arboren_US
dc.contributor.affiliationumDepartments of Pharmacology, University of Michigan, Ann Arboren_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97182/1/0091270010361256.pdf
dc.identifier.doi10.1177/0091270010361256en_US
dc.identifier.sourceThe Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceCarvalho B. Respiratory depression after neuraxial opioids in the obstetric setting. Anesth Analg. 2008; 107: 956 – 961.en_US
dc.identifier.citedreferenceVan de Heijning BJM, Van den Koekkoek‐Herik I, Maigret C, et al. Pharmacological assessment of the site of action of opioids on the release of vasopressin and oxytocin in the rat. Eur J Pharmacol. 1991; 197: 175 – 180.en_US
dc.identifier.citedreferenceVan de Heijning BJM, Van den Koekkoek‐Herik I, Van Wimersma Greidanus TB. The opioid receptor subtypes mu and kappa, but not delta, are involved in the control of the vasopressin and oxytocin release in the rat. Eur J Pharmacol. 1991; 209: 199 – 206.en_US
dc.identifier.citedreferenceDayanithi G, Stuenkel E, Nordmann JJ. Intracellular calcium and hormone release from nerve endings of the neurohypophysics in the presence of opioid agonists and antagonists. Exp Brain Res. 1992; 90: 539 – 545.en_US
dc.identifier.citedreferenceBrown CH, Russell JA, Leng G. Opioid modulation of magnocellular neurosecretory cell activity. Neurosci Res. 2000; 36: 97 – 120.en_US
dc.identifier.citedreferenceBicknell RJ, Leng G. Endogenous opiates regulate oxytocin but not vasopressin secretion from the neurohypophysis. Nature. 1982; 298: 161 – 162.en_US
dc.identifier.citedreferenceBondy CA, Gainer H, Russell JT. Dynorphin A inhibits and naloxone increases the electrically stimulated release of oxytocin but not vasopressin from the terminals of the neural lobe. Endocrinology. 1988; 122: 1321 – 1327.en_US
dc.identifier.citedreferenceShuster SJ, Riedl M, Li X, et al. The kappa opioid receptor and dynorphin co‐localize in vasopressin magnocellular neurosecretory neurons in guinea‐pig hypothalamus. Neuroscience. 2000; 96: 373 – 383.en_US
dc.identifier.citedreferenceGrell S, Fjalland B, Christensen JD. Biphasic effect of a kappa‐opioid receptor agonist on plasma oxytocin levels in rats. Eur J Pharmacol. 1989; 166: 41 – 48.en_US
dc.identifier.citedreferenceTrescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008; 11: S133 – S153.en_US
dc.identifier.citedreferenceO'Connor AB, Lang VJ, Quill TE. Eliminating analgesic meperidine use with a supported formulary restriction. Am J Med. 2005; 118: 885 – 889.en_US
dc.identifier.citedreferenceSeifert CF, Kennedy S. Meperidine is alive and well in the new millennium: Evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy. 2004; 24: 776 – 783.en_US
dc.identifier.citedreferenceVermeulen LC, Bollinger KA, Antonopoulos J, et al. Multifaceted approach to medication use policy development: the restriction of meperidine. Pharm Pract Manage Q. 1997; 16: 66 – 75.en_US
dc.identifier.citedreferenceMarcus MA, Gogarten G, Aken HV. Opioids in obstetrics: which route of administration with which opioid do we choose to establish effective analgesia? Eur J Anaesthesiol. 1998; 15: 140 – 146.en_US
dc.identifier.citedreferenceFriedman EA. Primigravid labor: a graphicostatistical analysis. Obstet Gynecol. 1955; 6: 567 – 589.en_US
dc.identifier.citedreferenceGreulich B, Tarrant B. The latent phase of labor: diagnosis and management. J Midwife Womens Hlth. 2007; 53: 190 – 198.en_US
dc.identifier.citedreferenceRussell JA, Leng G, Bicknell RJ. Opioid tolerance and dependence in the magnocellular oxytocin system: a physiological mechanism? Exper Physiol. 1995; 80: 307 – 340.en_US
dc.identifier.citedreferenceDouglas AJ, Dye S, Leng G, et al. Endogenous opioid regulation of oxytocin secretion through pregnancy in the rat. J Neuroendocrinol. 1993; 5: 307 – 314.en_US
dc.identifier.citedreferenceLeng G, Dye S, Bicknell RJ. Kappa‐opioid restraint of oxytocin secretion: plasticity through pregnancy. Neuroendocrinology. 1997; 66: 378 – 383.en_US
dc.identifier.citedreferenceKutlu S, Yilmaz B, Canpolat S, et al. Mu opioid modulation of oxytocin secretion in late pregnant and parturient rats: involvement of noradrenergic neurotransmission. Neuroendocrinology. 2004; 79: 197 – 203.en_US
dc.identifier.citedreferenceJi Y, Mei J, Lu S. Opposing effects of intracerebroventricularly injected norepinephrine on oxytocin and vasopressin neurons in the paraventricular nucleus of the rat. Neurosci Lett. 1998; 244: 13 – 16.en_US
dc.identifier.citedreferenceDondi D, Maggi R, Panerai AE, et al. Hypothalamic opiatergic tone during pregnancy, parturition and lactation in the rat. Neuroendocrinology. 1991; 53: 460 – 466.en_US
dc.identifier.citedreferenceBoersma CJ, Van Leeuwen FW. Neuron‐glia interactions in the release of oxytocin and vasopressin from the rat neural lobe: the role of opioids, other neuropeptides and their receptors. Neuroscience. 1994; 62: 1003 – 1020.en_US
dc.identifier.citedreferenceDouglas AJ, Russell JA. Endogenous opioid regulation of oxytocin and ACTH secretion during pregnancy and parturition. Prog Brain Res. 2001; 133: 67 – 82.en_US
dc.identifier.citedreferenceNeumann I, Russell JA, Landgraf R. Endogenous opioids regulate intracerebral oxytocin release during parturition in a region‐specific manner. Prog Brain Res. 1992; 91: 55 – 58.en_US
dc.identifier.citedreferenceNelson EE, Panksepp J. Brain substrates of infant‐mother attachment: contribution of opioids, oxytocin, and norepinephrine. Neurosci Biobehav Rev. 1998; 22: 437 – 452.en_US
dc.identifier.citedreferenceRussell JA, Leng G, Douglas AJ. The magnocellular oxytocin system, the fount of maternity: adaptations in pregnancy. Front Neuroendocrinol. 2003; 24: 27 – 61.en_US
dc.identifier.citedreferenceCenter for Disease Control and Prevention. Births: Final Data for 2006. January 7, 2009. http:www.cdc.gov. Accessed June 22, 2009.en_US
dc.identifier.citedreferenceUllman R, Dowswell T, Mori R. Parenteral opioids for maternal pain relief in labour. Cochrane Database Syst Rev. 2008;(4):CD007396.en_US
dc.identifier.citedreferenceDeVoe SJ, DeVoe K Jr., Rigsby WC, McDaniels BA. Effect of meperidine on uterine contractility. Am J Obstet Gyn. 1969; 105: 1004 – 1007.en_US
dc.identifier.citedreferenceFrost JJ, Wagner HN Jr., Dannals RF, et al. Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomograp. 1985; 9: 231 – 236.en_US
dc.identifier.citedreferenceWagner HN Jr. Radiolabeled drugs as probes of central nervous system neurons. Clin Chem. 1985; 31: 1521 – 1524.en_US
dc.identifier.citedreferenceSimantov R, Snyder SH. Opiate receptor binding in the pituitary gland. Brain Res. 1977; 124: 178 – 184.en_US
dc.identifier.citedreferenceDalayeun JF, Nores JM, Bergal S. Physiology of beta‐endorphin: a close‐up view and a review of the literature. Biomed Pharmacother. 1993; 47: 311 – 320.en_US
dc.identifier.citedreferenceJordan D, Tafani JAM, Ries C, et al. Evidence for multiple opioid receptors in the human posterior pituitary. J Neuroendocrinol. 1996; 8: 883 – 887.en_US
dc.identifier.citedreferenceWeerts EM, Kim YK, Wand GS, et al. Differences in δ‐ and μ‐opioid receptor blockade measured by positron emission tomography in naltrexone‐treated recently abstinent alcohol‐dependent subjects. Neuropsychopharmacology. 2008; 33: 653 – 665.en_US
dc.identifier.citedreferenceGutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Parker KL, Murri N, et al, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw‐Hill; 2006.en_US
dc.identifier.citedreferenceLutz‐Bucher B, Koch B. Evidence for a direct inhibitory effect of morphine on the secretion of posterior pituitary hormones. Eur J Pharmacol. 1980; 66: 375 – 378.en_US
dc.identifier.citedreferenceClarke G, Patrick G. Differential inhibitory action by morphine on the release of oxytocin and vasopressin from the isolated neural lobe. Neurosci Lett. 1983; 39: 175 – 180.en_US
dc.identifier.citedreferenceBicknell RJ, Leng G, Russell JA, Dyer RG, Mansfield S, Zhao BG. Hypothalamic opioids mechanisms controlling oxytocin neurons during parturition. Brain Res. 1988; 20: 743 – 749.en_US
dc.identifier.citedreferenceZhao BG, Chapman C, Bicknell RJ. Functional κ‐opioid receptors on oxytocin and vasopressin nerve terminals isolated from the rat neurohypophysis. Brain Res. 1988; 462: 62 – 66.en_US
dc.identifier.citedreferencePumford K, Leng G, Russell JA. Morphine actions on supraoptic oxytocin neurons in anaesthetized rats: tolerance after i.c.v. morphine infusion. J Physiol. 1991; 440: 437 – 454.en_US
dc.identifier.citedreferenceOrtiz‐Miranda S, Dayanithi G, Coccia V, et al. μ‐Opioid receptor modulates peptide release from rat neurohypophysial terminals by inhibiting Ca 2+ influx. J Neuroendocrinol. 2003; 15: 888 – 894.en_US
dc.identifier.citedreferenceOrtiz‐Miranda S, Dayanithi G, Custer E, Treistman SN, Lernos JR. μ‐Opioid receptor preferentially inhibits oxytocin release from neurohypophysial terminals by blocking R‐type Ca 2+ channels. J Neuroendocrinol. 2005; 17: 583 – 590.en_US
dc.identifier.citedreferenceZhao BG, Chapman C, Brown D, et al. Opioid‐noradrenergic interactions in the neurohypophysis: II. Does noradrenaline mediate the actions of endogenous opioids on oxytocin and vasopressin release? Neuroendocrinology. 1988; 48: 25 – 31.en_US
dc.identifier.citedreferenceBicknell RJ, Zhao BG, Chapman C, et al. Opioid inhibition of secretion from oxytocin and vasopressin nerve terminals following selective depletion of neurohypophysical catecholamines. Neurosci Lett. 1988; 93: 281 – 286.en_US
dc.identifier.citedreferenceKato M, Chapman C, Bicknell RJ. Activation of κ‐opioid receptors inhibits depolarization‐evoked exocytosis but not the rise in intracellular Ca 2+ in secretory nerve terminals of the neurohypophysis. Brain Res. 1992; 574: 138 – 146.en_US
dc.identifier.citedreferenceRussell JA, Coombes JE, Leng G, et al. Morphine tolerance and inhibition of oxytocin secretion by kappa‐opioids acting on the rat neurohypophysis. J Physiol. 1993; 469: 365 – 386.en_US
dc.identifier.citedreferenceZhao BG, Chapman C, Bicknell RJ. Opioid‐noradrenergic interactions in the neurohypophysis: I. Differential opioid receptor regulation of oxytocin, vasopressin, and noradrenaline release. Neuroendocrinology. 1988; 48: 16 – 24.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0091270010361256.pdf
Size:
175.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.